Fig. 7.

Overlapping NF-κB- and Sp1-binding sites are required for DEN-2-induced Apo2L/TRAIL activation. (a) The Apo2L/TRAIL sequence between nt −75 and −65 shares potential binding sites for NF-κB and Sp1. The Sp1 and NF-κB sites are underlined and boxed, respectively. (b) Effect of the −74/−65 deletion on Apo2L/TRAIL promoter activity in HepG2 cells infected with DEN-2. HepG2 cells were transfected with a luciferase plasmid that contained either the wild-type (ApoP/1056) or the deletion mutant version of the Apo2L/TRAIL promoter fragment −1056/+86 (ApoP/1056ΔκB). Activities are expressed relative to cells transfected with ApoP/1056 followed by mock-treatment, which were assigned a value of 1.